Click or scroll to zoom
Tap or pinch to zoom
Rituxan Hycela (rituximab/hyaluronidase human) 1400mg and 23400 Units Single-Dose Vial **Refrigerated Item**
Save 38%
Original price
$ 12,950.95
Current price
$ 7,999.95
SKU 50242-0108-01
Medical Professional License Required to Unlock Account
(Note: We don’t Fill Personal Prescriptions)
How to Order:
(Note: We don’t Fill Personal Prescriptions)
How to Order:
✔
Create an Account by Clicking “Login” on Top Right
✔
Next email a copy of medical License to Sales@mountainside-medical.com
✔
Time: License Approval in Usually Very Fast. Mostly likely 30 to 90 minutes if between Monday to Friday 8 am to
4 pm EST Business Days. Weekends will be approved on Monday.
✔
Once Approved you will receive a Welcome email that your account is approved to purchase RX items.
✔ Login and Start ordering.
✔If you should have any trouble or have a question, Please Call Toll-Free: 1-888-687-4334
✔All RX Deliveries are sent Signature Required
Rituxan hycela is a chemotherapy drug that is used to treat a range of cancers, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. It is a monoclonal antibody, which means that it is designed to target and destroy a specific type of cell. Rituxan hycelA works by binding to the surface of cancer cells and destroying them. This can be a very effective treatment for cancer, but it can also cause some side effects, such as nausea and vomiting.
RITUXAN HYCELA is a combination of rituximab, a CD20-directed cytolytic antibody, and hyaluronidase human, an endoglycosidase, indicated for the treatment of adult patients with:
- Follicular Lymphoma (FL) (1.1)
RITUXAN HYCELA is a combination of rituximab, a CD20-directed cytolytic antibody, and hyaluronidase human, an endoglycosidase, indicated for the treatment of adult patients with:
- Follicular Lymphoma (FL) (1.1)
- Relapsed or refractory, follicular lymphoma as a single agent Previously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single- agent maintenance therapy
- Non-progressing (including stable disease), follicular lymphoma as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy
- Previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens
- Previously untreated and previously treated CLL in combination with fludarabine and cyclophosphamide (FC)
